Nutritional interventions in treating menopause-related sleep disturbances: a systematic review
Source : https://pubmed.ncbi.nlm.nih.gov/37695299/
PROSPERO registration no. CRD42021262367.
Most studies suggest nutritional interventions benefit subjective sleep disturbances in menopause. However, due to study heterogeneity and low methodological quality, more high-quality trials are needed.
Share
Ovarian Suppression: Early Menopause and Late Effects
Source : https://pubmed.ncbi.nlm.nih.gov/38478329/
Around 90% of breast tumours are diagnosed in the early stage, with approximately 70% being hormone receptor-positive. The cornerstone of adjuvant therapy for early-stage hormone receptor-positive breast cancer is endocrine...
Ovarian function suppression in hormone receptor-positive breast cancer, while effective, can impact quality of life due to side effects. Clinicians must proactively manage these effects for better adherence and outcomes.
Share
Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review
Source : https://pubmed.ncbi.nlm.nih.gov/36651193/
The findings of this systematic review support the use of serum AMH to study the age of menopause in population studies. The increased sensitivity of current AMH assays provides improved...
The findings of this systematic review support the use of serum AMH to study the age of menopause in population studies. The increased sensitivity of current AMH assays provides improved accuracy for the prediction of imminent menopause, but diagnostic use for individual patients has not been rigorously examined.
Share
Cognitive Decline in Early and Premature Menopause
Source : https://pubmed.ncbi.nlm.nih.gov/37047549/
Early and premature menopause, or premature ovarian insufficiency (POI), affects 1% of women under the age of 40 years. This paper reviews the main aspects of early and premature menopause...
Early menopause increases cognitive decline risk; menopausal hormone therapy may reduce mild cognitive impairment and Alzheimer's risk. Multidisciplinary care is crucial for mental health in affected women.
Share
Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT
Source : https://pubmed.ncbi.nlm.nih.gov/36734148/
Daily fezolinetant 30 and 45 mg were efficacious and well tolerated for treating moderate to severe VMS associated with menopause.
Daily fezolinetant 30 and 45 mg were efficacious and well tolerated for treating moderate to severe VMS associated with menopause.
Share